PMID- 24903150
OWN - NLM
STAT- MEDLINE
DCOM- 20150428
LR  - 20211021
IS  - 1472-6882 (Electronic)
IS  - 1472-6882 (Linking)
VI  - 14
DP  - 2014 Jun 6
TI  - Effects of JSOG-6 on protection against bone loss in ovariectomized mice through 
      regulation of osteoblast differentiation and osteoclast formation.
PG  - 184
LID - 10.1186/1472-6882-14-184 [doi]
AB  - BACKGROUND: JSOG-6 is used as a traditional medicine to relieve the symptoms 
      associated with inflammation, rheumatism, and osteoporosis in Korea. In the 
      present study, we investigated the effects of JSOG-6 on bone loss prevention both 
      in in vitro and in vivo as well as its underlying mechanism of action. METHODS: 
      Protection against bone loss was assessed in an ovariectomized (OVX) mouse model. 
      Bone microarchitecture was measured using a micro-computed tomography to detect 
      the parameters of three-dimensional structure of a trabecular bone. Serum 
      biomarkers were also evaluated in an OVX-induced model. Osteoclasts derived from 
      mouse bone marrow cells (BMCs) and osteoblastic MC3T3-E1 cells were also employed 
      to investigate the mechanism of action. RESULTS: Oral administration of JSOG-6 
      significantly increased the bone mineral density (BMD) of the femur in OVX mice 
      in vivo. Especially, the reduced Tb.No (trabecular bone number) in the OVX group 
      was significantly recovered by JSOG-6 treatment. The serum levels of alkaline 
      phosphatase (ALP), osteocalcin, C-terminal telopeptide, and tartrate-resistant 
      acid phosphatase, biomarkers of bone resorption, were significantly elevated in 
      OVX mice, but JSOG-6 effectively inhibited the increase in OVX mice. JSOG-6 was 
      also found to enhance the osteoblastic differentiation and maturation with the 
      increase of the density and ALP activity, a marker of osteoblastic 
      differentiation, as well as calcium deposition, a marker of osteoblastic 
      maturation in MC3T3-E1 cells. The effects of JSOG-6 on osteoblastic 
      differentiation were also associated in part with the increase of ALP and OPN 
      mRNA expressions and the decrease of RANKL mRNA expression in MC3T3-E1 cells. 
      CONCLUSIONS: The findings demonstrate that JSOG-6 induced protection against bone 
      loss in OVX mice, and its anti-osteoporotic property might be, in part, a 
      function of the stimulation of osteoblast differentiation and the inhibition of 
      osteoclast formation. These findings suggest that JSOG-6 might be an applicable 
      therapeutic traditional medicine for the regulation of the osteoporotic response.
FAU - Chung, Hwa-Jin
AU  - Chung HJ
FAU - Cho, Lan
AU  - Cho L
FAU - Shin, Joon-Shik
AU  - Shin JS
FAU - Lee, Jinho
AU  - Lee J
FAU - Ha, In-Hyuk
AU  - Ha IH
FAU - Park, Hyen Joo
AU  - Park HJ
FAU - Lee, Sang Kook
AU  - Lee SK
AD  - College of Pharmacy, Natural Products Research Institute, Seoul National 
      University, San 56-1 Sillim-dong, Gwanak-gu, Seoul 151-742, Korea. 
      sklee61@snu.ac.kr.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140606
PL  - England
TA  - BMC Complement Altern Med
JT  - BMC complementary and alternative medicine
JID - 101088661
RN  - 0 (Isoenzymes)
RN  - 0 (JSOG-6)
RN  - 0 (Plant Extracts)
RN  - 0 (RANK Ligand)
RN  - 104982-03-8 (Osteocalcin)
RN  - EC 3.1.3.1 (Alkaline Phosphatase)
RN  - EC 3.1.3.2 (Acid Phosphatase)
RN  - EC 3.1.3.2 (Tartrate-Resistant Acid Phosphatase)
SB  - IM
MH  - Acid Phosphatase
MH  - Alkaline Phosphatase/blood
MH  - Animals
MH  - Bone Density/drug effects
MH  - Bone Resorption/*prevention & control
MH  - Bone and Bones/metabolism
MH  - Cell Differentiation/drug effects
MH  - Cell Line
MH  - Female
MH  - Femur
MH  - Gene Expression/drug effects
MH  - Humans
MH  - Isoenzymes
MH  - Mice
MH  - Mice, Inbred ICR
MH  - Osteoblasts/*drug effects/metabolism
MH  - Osteocalcin/blood
MH  - Osteoclasts/*drug effects
MH  - Osteogenesis/drug effects
MH  - Osteoporosis/blood/*drug therapy
MH  - Ovariectomy
MH  - Phytotherapy
MH  - Plant Extracts/pharmacology/*therapeutic use
MH  - RANK Ligand/metabolism
MH  - Republic of Korea
MH  - Tartrate-Resistant Acid Phosphatase
MH  - X-Ray Microtomography
PMC - PMC4066836
EDAT- 2014/06/07 06:00
MHDA- 2015/04/29 06:00
PMCR- 2014/06/06
CRDT- 2014/06/07 06:00
PHST- 2013/12/13 00:00 [received]
PHST- 2014/05/29 00:00 [accepted]
PHST- 2014/06/07 06:00 [entrez]
PHST- 2014/06/07 06:00 [pubmed]
PHST- 2015/04/29 06:00 [medline]
PHST- 2014/06/06 00:00 [pmc-release]
AID - 1472-6882-14-184 [pii]
AID - 10.1186/1472-6882-14-184 [doi]
PST - epublish
SO  - BMC Complement Altern Med. 2014 Jun 6;14:184. doi: 10.1186/1472-6882-14-184.